Glaucoma

The primary outcome of the trial is intraocular pressure (IOP) measured using Goldmann Applanation Tonometry (GAT).

Glaukos finishes US pivotal enrollment for Preserflo MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

A large real-world cohort study by Takashi Nishida, MD, PhD et al finds OSA is associated with elevated glaucoma risk.

ZEISS partners with Envision to expand evidence-backed VR perimetry, enabling more accessible, gamified home visual field testing for glaucoma monitoring.

Preservative-free bimatoprost gel now offers once-daily glaucoma and ocular hypertension IOP reduction, aiming to boost comfort, tolerability, and long-term adherence.

The emerging technology offers a new paradigm for treating a group of eye diseases.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

The review analyzed 46 reports from 43 unique studies.

Mitch Ibach, OD, FAAO; Nate Lighthizer, OD, FAAO; and Austin Lifferth, OD, FAAO, share practical insights on identifying early disease and more.

Across mild, moderate, and severe disease, 3 cases show how timely glaucoma intervention can reduce medications and preserve sight.

Mitch Ibach, OD, FAAO; Nate Lighthizer, OD, FAAO; and Austin Lifferth, OD, FAAO, discuss how they evaluate patients with borderline findings but significant risk factors

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

This case study highlights the tension between what patients report and what clinicians observe and measure.

The analysis included 12,183,254 patients, with 304,823 identified as smokers and 11,878,431 as non-smokers.

Mt. Sinai introduced the miDOC system at the ASCRS annual meeting.

AlloSpan Canal is designed to address limitations associated with existing approaches by combining nitinol-guided canaloplasty with biological reinforcement.

The prospective, multicenter study enrolled 318 patients across 20 US sites.

Pathik Amin, OD, FAAO, gave a presentation to the optometry cohort at the conference on glaucoma management, focusing on surgical options and recent advancements.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

The study included 144 patients with glaucoma or ocular hypertension who underwent 24-hour IOP monitoring between October 2023 and April 2024.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).